China approves Brii Biosciences' COVID-19 treatment

China's medical products regulator said on Wednesday it had approved the use of Brii Biosciences' neutralising antibody cocktail for COVID-19, the first treatment of its type against the virus given the go-ahead in the country. The combination of BRII-196/BRII-198 showed a 78% reduction of hospitalization and death in non-hospitalized COVID-19 patients at high risk of developing severe disease in a Phase III clinical trial, Brii said in October. The medicine from a Brii subsidiary was approved to treat mild COVID-19 and the disease of 'normal type' with high risk of progressing to hospitalization or death in adults and minors aged 12-17, the National Medical Products Administration said.